Oculis FY26 H1 net loss narrows to CHF 38.82 million
Reuters2026/08/06 20:06- Oculis posted a net loss of CHF 38.82 million for the six months ended June 30, narrowing from CHF 58.59 million a year earlier.
- Operating loss widened to CHF 45.3 million from CHF 40.74 million, while finance result swung to CHF 6.38 million from a loss of CHF 17.86 million.
- R&D expenses edged up to CHF 29.33 million from CHF 29.68 million; G&A costs rose to CHF 16.49 million from CHF 11.61 million.
- Cash, cash equivalents and short-term investments totaled $282.3 million at June 30, supporting runway into 2H 2029.
- PIONEER-1 Privosegtor site activations advanced; FDA feedback cleared no added preclinical work for acute MS relapse IND, targeted for Q4 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Xenia Hôtellerie Solution announces extraordinary shareholder meeting
Community Reacts As Pundit Claims XRP Will Be Priced At $2,953 By Q2 2027
Colgate-Palmolive (CL.US) plans to sell part of its personal care brands, with a total transaction amount possibly exceeding 1.1 billions USD.
According to sources familiar with the matter, Colgate is exploring the sale of some of its mass-market personal care brands. The company currently plans to divest only a few brands within its personal care business, and the combined sale price may exceed 1 billion dollars.
EdiliziAcrobatica announces shareholder meeting notice
Crypto prices
More
